Zacks Investment Research Lowers Vincerx (NASDAQ:VINC) to Hold

Zacks Investment Research downgraded shares of Vincerx (NASDAQ:VINCGet Rating) from a buy rating to a hold rating in a research report sent to investors on Thursday morning, Zacks.com reports.

According to Zacks, “Vincerx Pharma Inc. is a biopharmaceutical company. It focuses on unmet medical needs of patients with cancer through paradigm-shifting therapeutics. Vincerx Pharma Inc. is based in PALO ALTO, Calif. “

VINC has been the subject of a number of other reports. Chardan Capital cut their price objective on Vincerx from $30.00 to $14.00 in a research report on Wednesday, March 30th. B. Riley cut their price target on shares of Vincerx from $26.00 to $12.00 in a research note on Tuesday, April 12th. SVB Leerink lowered their target price on shares of Vincerx from $24.00 to $20.00 and set an outperform rating on the stock in a research report on Wednesday, March 30th. Finally, HC Wainwright upped their price target on shares of Vincerx from $25.00 to $28.00 and gave the company a buy rating in a research report on Tuesday, March 29th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of Buy and a consensus price target of $18.89.

Shares of Vincerx stock traded up $0.02 on Thursday, reaching $2.54. The company’s stock had a trading volume of 91,969 shares, compared to its average volume of 114,314. Vincerx has a 52-week low of $2.40 and a 52-week high of $18.43. The company has a market capitalization of $53.49 million, a P/E ratio of -1.11 and a beta of 1.16. The stock has a 50-day moving average price of $4.01 and a 200-day moving average price of $8.15.

Vincerx (NASDAQ:VINCGet Rating) last posted its quarterly earnings results on Tuesday, March 29th. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.08. Research analysts expect that Vincerx will post -3.14 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC acquired a new position in shares of Vincerx in the 3rd quarter valued at $25,000. Royal Bank of Canada raised its position in Vincerx by 390.1% in the third quarter. Royal Bank of Canada now owns 1,578 shares of the company’s stock worth $26,000 after purchasing an additional 1,256 shares in the last quarter. Citigroup Inc. lifted its stake in Vincerx by 219.2% during the fourth quarter. Citigroup Inc. now owns 4,833 shares of the company’s stock worth $49,000 after purchasing an additional 3,319 shares during the period. Allspring Global Investments Holdings LLC acquired a new stake in shares of Vincerx during the 4th quarter worth about $83,000. Finally, Wells Fargo & Company MN grew its position in Vincerx by 73.0% during the 2nd quarter. Wells Fargo & Company MN now owns 6,500 shares of the company’s stock worth $84,000 after acquiring an additional 2,742 shares during the last quarter. 79.54% of the stock is owned by hedge funds and other institutional investors.

Vincerx Company Profile (Get Rating)

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies.

Further Reading

Get a free copy of the Zacks research report on Vincerx (VINC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Vincerx (NASDAQ:VINC)

Receive News & Ratings for Vincerx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vincerx and related companies with MarketBeat.com's FREE daily email newsletter.